BioCryst Pharmaceuticals, Inc.
BioCryst Pharmaceuticals, Inc. (BCRX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · BCRX · as of Sep 30, 2025
Ownership Breakdown
296
Institutional Holders
▼ 13 vs Q2
$1.48B
Total Inst. Value
▼ $291.89M vs Q2
209.89M
Shares Outstanding
freeFloat 86.84%
194.20M
13F Shares Held
▼ 3.03M vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
BCRX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
VANGUARD GROUP INC biological products, (no diagnostic substances) | 21.79M | 10.42% | 10.42% | $165.39B | Nov 7, 2025 | ▲ 1.25M |
BLACKROCK, INC. biological products, (no diagnostic substances) | 21.25M | 10.16% | 10.16% | $161.26B | Nov 12, 2025 | ▼ 180.0K |
DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) biological products, (no diagnostic substances) | 12.17M | 5.82% | 5.82% | $92.36B | Nov 14, 2025 | ▲ 7.48M |
STATE STREET CORP biological products, (no diagnostic substances) | 9.81M | 4.69% | 4.69% | $74.44B | Nov 14, 2025 | ▲ 1.30M |
KYNAM CAPITAL MANAGEMENT, LP biological products, (no diagnostic substances) | 9.39M | 4.49% | 4.49% | $71.27B | Nov 14, 2025 | ▲ 926.5K |
UBS GROUP AG biological products, (no diagnostic substances) | 5.97M | 2.85% | 2.85% | $45.30B | Nov 13, 2025 | ▲ 353.1K |
ALKEON CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 5.46M | 2.61% | 2.61% | $41.47B | Nov 14, 2025 | ▼ 250.0K |
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP biological products, (no diagnostic substances) | 5.23M | 2.50% | 2.50% | $39.67B | Nov 13, 2025 | ▲ 947.4K |
MORGAN STANLEY biological products, (no diagnostic substances) | 5.20M | 2.49% | 2.49% | $39.49B | May 27, 2026 | ▼ 126.7K |
GEODE CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 5.05M | 2.42% | 2.42% | $38.35B | Nov 12, 2025 | ▼ 2.3K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
22
Increased
+19.57M shares2
New Positions
first time holders25
Decreased
−14.24M shares0
Sold Out
fully exitedNet shares change (top 50)
+5.34M
+19.57M / −14.24M
Net new holders
-1
2 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
BCRX insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Milne Jill C. director | May 29, 2026 | Award | 1,262 | $8.91 | $11.2K | 16.6K | Form 4 ↗ |
Stonehouse Jon P director | May 29, 2026 | Award | 631 | $8.91 | $5.6K | 1.32M | Form 4 ↗ |
McKee Amy E director | May 29, 2026 | Award | 631 | $8.91 | $5.6K | 31.9K | Form 4 ↗ |
MILANO VINCENT director | May 29, 2026 | Award | 1,122 | $8.91 | $10.0K | 93.2K | Form 4 ↗ |
Frank Steven director | May 29, 2026 | Award | 1,262 | $8.91 | $11.2K | 20.2K | Form 4 ↗ |
McKee Amy E director | May 18, 2026 | Sale | 11,180 | $8.97 | $100.3K | 31.3K | Form 4 ↗ |
Barnes Alane P Chief Legal Officer | May 13, 2026 | Sale | 62,500 | $9.54 | $596.3K | 400.7K | Form 4 ↗ |
Menon Sandeep Chief R&D Officer | Apr 6, 2026 | Award | 441,350 | $9.47 | $4.18M | 441.4K | Form 4 ↗ |
Menon Sandeep Chief R&D Officer | Apr 6, 2026 | Award | 205,150 | — | — | 205.2K | Form 4 ↗ |
HEGGIE THERESA director | Mar 20, 2026 | Sale | 49,933 | $10.11 | $504.8K | 65.4K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
BioCryst Pharmaceuticals, Inc. (BCRX) is primarily owned by institutional investors, who hold approximately 92.5% of total shares outstanding. Company insiders own approximately 13.16%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of BioCryst Pharmaceuticals, Inc. is VANGUARD GROUP INC, holding approximately 21.79 million shares — equal to 10.42% of outstanding shares — as of September 30, 2025.
A total of 296 institutional investors currently hold BCRX stock, with a combined institutional value of approximately $1.48 billion as of the most recent 13F filing period.
Frequently asked questions
BCRX ownershipBioCryst Pharmaceuticals, Inc. (BCRX) is primarily owned by institutional investors, who hold approximately 92.5% of shares. The largest shareholder is VANGUARD GROUP INC with a 10.42% stake. Company insiders hold 13.16%. Data sourced from SEC Form 13F as of September 30, 2025.